Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on Monday

Bolt Biotherapeutics (NASDAQ:BOLT) is expected to issue its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($2.85) per share and revenue of $1.50 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Thursday, March 12th. The company reported ($3.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.27) by $0.43. The business had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $0.67 million. Bolt Biotherapeutics had a negative return on equity of 92.54% and a negative net margin of 433.74%.

Bolt Biotherapeutics Stock Down 1.7%

Shares of BOLT stock traded down $0.09 during mid-day trading on Monday, hitting $4.98. 3,085 shares of the stock traded hands, compared to its average volume of 25,536. Bolt Biotherapeutics has a 52-week low of $3.91 and a 52-week high of $9.25. The stock has a market cap of $9.55 million, a P/E ratio of -0.28 and a beta of 1.10. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.59 and a quick ratio of 3.59. The stock’s fifty day moving average is $4.60 and its two-hundred day moving average is $5.18.

Analysts Set New Price Targets

Several analysts recently issued reports on BOLT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Friday, March 13th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $34.00.

Institutional Trading of Bolt Biotherapeutics

Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its stake in shares of Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after purchasing an additional 26,400 shares during the period. Susquehanna International Group LLP acquired a new stake in Bolt Biotherapeutics during the 3rd quarter worth approximately $89,000. Shay Capital LLC purchased a new position in Bolt Biotherapeutics in the 3rd quarter valued at approximately $85,000. Finally, Squarepoint Ops LLC grew its stake in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after acquiring an additional 2,448 shares in the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.